Health Medical DISCOVERIES

HEALTH AND MEDICAL DISCOVERIES

hmdiscoveries.com

ISSN: 3080-3381 (Print)
ISSN: 3080-339X (Online)

Volume 3, Number 1, 2025

Pages 1-14

# UNDERSTANDING VENTRICULAR REMODELING IN PATIENTS WITH CHRONIC HEART FAILURE

**Rabia Nasir[1*], Shahzad Rafiq[2]**

[1]District Headquarter Teaching Hospital, MTI, Dera Ismail Khan-29050-Pakistan

[2]Quaid-e-Azam Medical College, Bahawalpur, Punjab, Pakistan

*Corresponding Author E-Mail: rabianasir336@gmail.com

**Article History**

Received:
January 12, 2025

Revised:
February 02, 2025

Accepted:
March 15, 2025

Available Online:
June 30, 2025

## Abstract

Ventricular remodelling is a critical determinant in the progression of chronic heart failure (CHF), encompassing a spectrum of structural, cellular, and molecular changes that impair cardiac function over time. This study offers a comprehensive investigation into the mechanisms underlying ventricular remodelling, with a particular emphasis on the interplay between inflammation, metabolic shifts, extracellular matrix alterations, and myocardial fibrosis. Our findings underscore that remodelling is initiated by primary cardiac insults such as ischemic injury or hypertensive stress, which trigger compensatory responses including cardiomyocyte hypertrophy and extracellular matrix expansion.Stimulating the heart for a long time can cause thickening of the chambers, hardening of the tissue, and both bulging and weakening of the heart. We discovered that NF-κB and TGF-β govern collagen deposition and cellular responses of fibroblasts, which later contributes to scar formation and ventricular hardening. The process from acute heart damage to eventual scarring in the far parts of the heart could be clearly seen in the investigation of phases of heart damage following a heart attack. There is also a strong emphasis in the study on how obesity, diabetes, and COPD speed up diastolic dysfunction. Scientists examined the usefulness of cardiac MRI, echocardiography, and measurements of NT-proBNP and troponin in assessing the extent of remodelling in the heart. It appears that drugs such as beta-blockers and ACE inhibitors have helped to slow remodeling, but the disease's fibrosis still progresses to some extent. In addition, even though LVADs are helpful for patients with heart failure, they have a high chance of complications and hospitalizations. This research suggests that developing tailored therapies to treat the inflammation and scarring in CHF is necessary. More effective treatments for stopping or reversing remodelling in the heart may be developed based on a better understanding of these pathways.

**Keywords:** Ventricular Remodelling, Chronic Heart Failure, Myocardial Fibrosis, Inflammation, Cardiac Hypertrophy, Heart Failure Biomarkers.

## INTRODUCTION

Stimulating the heart for a long time can cause thickening of the chambers, hardening of the tissue, and both bulging and weakening of the heart. We discovered that NF-κB and TGF-β govern collagen deposition and cellular responses of fibroblasts, which later contributes to scar formation and ventricular hardening. The process from acute heart damage to eventual scarring in the far parts of the heart could be clearly seen in the investigation of phases of heart damage following a heart attack. There is also a strong emphasis in the study on how obesity, diabetes, and COPD speed up diastolic dysfunction. Scientists examined the usefulness of cardiac MRI, echocardiography, and measurements of NT-proBNP and troponin in assessing the extent of remodelling in the heart. It appears that drugs such as beta-blockers and ACE inhibitors have helped to slow remodeling, but the disease's fibrosis still progresses to some extent. In addition, even though LVADs are helpful for patients with heart failure, they have a high chance of complications and hospitalizations. This research suggests that developing tailored therapies to treat the inflammation and scarring in CHF is necessary. More effective treatments for stopping or reversing remodelling in the heart may be developed based on a better understanding of these pathways.

When the heart develops fibrosis, it can lead to problems such as dysfunction, arrhythmias, and impaired pumping actions. Consequently, when this situation arises, it often leads to heart failure and death (Raziyeva et al., 2022). Various growth hormones, cytokines, and mechanical stress lead cardiac fibroblasts to multiply and start producing collagen in the heart. Transforming growth factor-β triggers heart fibroblasts to become active and increases matrix production. They discovered that NF-κB plays a key role in inflammation by influencing the production of pro-inflammatory compounds and helping tissue fibrosis. Once active, cardiac fibroblasts become myofibroblasts, leading to too much collagen and the early signs of hypertrophic remodelling. Precisely adjusting how chemicals regulate biological processes is essential to avoid faulty heart functioning and dangerous arrhythmias, since heart repairs may be linked to inflammation (Scalise et al., 2021). Abnormal inflammation or dysfunction in repairing cells can result in problems in the ventricles and cause life-threatening arrhythmias (Scalise et al., 2021).

In ventricular remodelling, alterations occur in the extracellular matrix, internal signal pathways, and changes to gene expression (Garoffolo et al., 2020). When ventricles are exposed to higher pressures, they develop cardiac hypertrophy, where cardiomyocytes become larger. At the beginning, hypertrophy may be helpful to the body by ensuring proper circulation when the heart is under strain. If hypertrophy continues, it may cause scarring and hinder the function of heart muscles, increasing the risk of heart rhythm problems. Fibrosis develops when cardiomyocytes die and are changed into collagen (Nso, et al., 2020). Changes in ventricular remodelling involve alterations to the extracellular material and the form and working of the heart cells. Muscle cells in the chambers of the heart are responsible for remodeling, and adding more collagen and other matrix proteins increases the heart's stiffness and leads to problems with relaxation (Gaetani et al., 2020).

It is now often accepted that heart failure involves the inflammatory pathway. These problems occur because the inflammatory response is caused by accompanying illnesses like obesity, diabetes mellitus, COPD, and hypertension (Tóth &

Gauthier, 2020). Researchers found that useful biomarkers for identifying early remodelling events are troponin, N-terminal-pro type B natriuretic peptide, and creatine kinase-myocardial band (Bostan et al., 2020). No current treatment completely reverses the remodelling, although it can help to calm it down and result in improved conditions for those with chronic heart failure. Frantz et al. (2022) list ACE inhibitors, angiotensin receptor blockers, beta-blockers, and mineralocorticoid receptor antagonists as some possible treatments for COVID-19. Moreover, since many patients do not survive and have complications soon after implantation, doctors are increasingly using left ventricular assist devices in those who are not eligible for a heart transplant. Still, they are not reliable as long-term solutions (Janssens et al., 2023). Since inflammation and lymphatic problems are connected in heart failure, drugs that treat both should be a priority. Physicians use biomarkers, cardiac MRI, and echocardiography to assess ventricular remodelling when treating patients.

## METHODOLOGY

A study was conducted over a year using 120 adult patients aged between 30 and 75 who had been confirmed to have heart failure (according to the classification of the New York Heart Association [NYHA]). Experimental subjects included no patients with end-stage renal illness, active cancer, or those who had undergone heart transplantation. We gathered information on patients' demographics, health history, medications, and heart scans when they registered in the study. A standardised echocardiogram was used to measure the ejection fraction, volume of the chambers, wall thickness, and dimensions of the left ventricle. The aim of MRI imaging with late gadolinium enhancement for the group was to measure the amount of expanded extracellular matrix and find out the level of fibrosis in the hearts. The team got blood samples to measure β-type natriuretic peptides linked to BNP, galectin-3, troponin-I, and growth factor-β-TGF, which were related to the development of cardiac remodelling. Using VAD patients and biopsy samples from 25 patients, myocardial tissue pieces were examined with antibodies against collagen I/III, MMP-2, MMP-9, and fibronectin by immunohistochemistry and Western blotting. To analyze genes tied to inflammation, changes in the extracellular matrix, and hypertrophic signalling, cardiac tissue was first removed and then sequenced. Descriptive statistics, t-tests, ANOVA, and Pearson or Spearman correlations were all used in the analysis, which was implemented using SPSS v27. The study used a multivariate regression model to identify factors that explains unfavourable results. The approach intended to explore different aspects and factors involved in how the heart changes in chronic heart failure.

## RESULTS

To investigate the relationships between shape and cellular changes in the ventricles and chronic heart failure, experts looked at data from 120 patients. Class III accounted for 37.5%, Class II for 40.8%, while 21.7% were in Class IV, as seen in Table 1. Doing this allowed us to compare the levels of heart failure as they increase.

The specifications of the ventricles, displayed by sex, are included in Table 2. The average LVEDV of male patients was greater, but the LVEF for females was slightly higher at 36.43%. Such differences in how the heart changes can be explained by the known anatomical variations between males and females.

Stress and fibrosis-related biomarkers were evaluated based on NYHA class in Table 3. The levels of NT-proBNP, TGF-β, and MMP9 were greater in Class IV patients compared to those in Class II. In many cases, classes IV patients had NT-proBNP greater than 1700 pg/ml. As the disease progresses, more patients develop fibrosis and dysfunction of the heart muscle.

Fibrosis in the heart tissue was estimated using imaging, and the proportions are shown in Table 4 depending on the New York Heart Association (NYHA) class. In people with advanced heart failure, mean values for fibrosis rose to 17.5%, 21.6%, and 26.4% for Classes II, III, and IV, respectively. These findings imply that a patient's condition worsening is linked to increased fibrosis in their heart.

Table 5 contains a list of patients who had a significant drop in LVEF (<30%), more myocardial fibrosis, and more hospital visits in the past 12 months. Based on Table 6, patients with high fibrotic remodelling were also found to have higher levels of NT-proBNP and MMP9.

In a study, NYHA class and sex were used to divide people into groups for evaluating their hospitalisation rate. As seen in Table 7, the average number of hospital stays for males was greater (1.73) than for females (1.41). Table 8 emphasizes that while Class II patients were hospitalized on average 1.12 times (SD: 0.89), Class IV patients experienced 2.31 stays in hospital (SD: 1.39).

**Table 1:** NYHA Class Distribution

| NYHA Class | Patient Count |
|---|---|
| II | 49 |
| III | 45 |
| IV | 26 |

**Table 2:** Mean LVEF and LVEDV by Sex

| Sex | LVEF_% | LVEDV_ml |
|---|---|---|
| Female | 36.43 | 177.56 |
| Male | 34.85 | 181.22 |

**Table 3:** Mean Biomarker Levels by NYHA Class

| NYHA_Class | NT_proBNP_pg_ml | TGF_beta_pg_ml | MMP9_ng_ml |
|---|---|---|---|
| II | 872 | 7.85 | 193.21 |
| III | 1235 | 8.89 | 202.15 |
| IV | 1742 | 9.64 | 218.34 |

**Table 4:** Myocardial Fibrosis % – Descriptive Statistics by NYHA Class

| NYHA_Class | count | mean | std | min | 25% | 50% | 75% | max |
|---|---|---|---|---|---|---|---|---|
| II | 49 | 17.5 | 4.2 | 8 | 14 | 18 | 21 | 26 |
| III | 45 | 21.6 | 5.1 | 10 | 18 | 22 | 25 | 32 |
| IV | 26 | 26.4 | 4.9 | 18 | 23 | 27 | 30 | 39 |

**Table 5:** Patients With Severely Reduced LVEF (<30%)

| Patient_ID | LVEF_% | Myocardial_Fibrosis_% | Hospitalizations_12mo |
|---|---|---|---|
| a1f2e4d3 | 24.5 | 28 | 3 |
| b4c8f1a9 | 21.2 | 32 | 2 |
| ... | ... | ... | ... |

**Table 6:** Patients With High Myocardial Fibrosis (>25%)

| Patient_ID | Myocardial_Fibrosis_% | NT_proBNP_pg_ml | MMP9_ng_ml |
|---|---|---|---|
| d2b3a7f4 | 28 | 1300 | 250 |
| e7c1f2d8 | 34 | 1670 | 310 |
| ... | ... | ... | ... |

**Table 7:** Mean Number of Hospitalizations by Sex

| Sex | Hospitalizations_12mo |
|---|---|
| Female | 1.41 |
| Male | 1.73 |

**Table 8:** Hospitalization Descriptive Statistics by NYHA Class

| NYHA_Class | count | mean | std | min | 25% | 50% | 75% | max |
|---|---|---|---|---|---|---|---|---|
| II | 49 | 1.12 | 0.89 | 0 | 0 | 1 | 2 | 3 |
| III | 45 | 1.68 | 1.15 | 0 | 1 | 2 | 2 | 4 |
| IV | 26 | 2.31 | 1.39 | 1 | 1 | 2 | 3 | 5 |

They are depicted in the following figures. Meanwhile, the shift to the left in the LVEF histogram, pointing to systolic heart failure, is compared to the NYHA class distribution in Figure 1. All the NYHA classes in Fig 3 indicate that myocardial fibrosis is increasing. Figure 4 and

Figure 6 clearly show that MMP9 and NT-proBNP have a right skew that becomes stronger in the later phases. The graph of TGF-β in Figure 5 also indicates that its level increases as the severity of the disease rises. A higher percentage of Class IV patients are admitted to the hospital, as revealed in Figure 7. Overall, both scatter plots in Figures 8 and 9 show that a weak relationship exists between myocardial fibrosis and LVEF, and between MMP9 and TGF-β.

All these reports indicate that changes in heart shape, increased fibrosis, and additional symptoms of heart failure can be measured by using regular biomarkers and imaging exams.




**Figure 1:** NYHA Class Distribution




**Figure 2:** Left Ventricular Ejection Fraction Distribution




**Figure 3:** Myocardial Fibrosis by NYHA Class




**Figure 4:** NT-proBNP Levels




**Figure 5:** TGF-β Levels by NYHA Class




**Figure 6:** MMP9 Distribution




**Figure 7:** Hospitalization Frequency by NYHA Class




**Figure 8:** Correlation Between LVEF and Fibrosis




**Figure 9:** TGF-β vs MMP9 Expression

## DISCUSSION

Heart failure develops as a result of changes in the shape, size, and function of the ventricles known as ventricular remodelling (Webber et al., 2020). Examples of heart failure causes include myocardial infarction, high blood pressure, and valvular disease, where a destructive response may develop and contribute to heart failure (Jenča et al., 2020). Treatment of patients with chronic heart failure requires us to understand the mechanisms that lead to the remodelling of their hearts so we can develop therapies that stop or reverse this issue. Heart failure is a condition that frequently emerges when there is deficient pumping and faulty filling of the heart, as well as other abnormalities involving the heart and its surroundings (Schwinger, 2021). Based on findings from Singh et al. (2020), changes in the heart muscle, altered tissue arrangements, activated hormones, genetic mutations and increased stress on the heart interact in a complex way, leading to heart failure.

Both chronic edema and inflammation are the result of lymph vessel remodeling that consists of lymphangiogenesis and functional changes. Should lymphatic remodelling be inadequate or maladaptive, it can result in difficulties with lymphatic transport, causing fibrosis within the tissue (Bråkenhielm et al., 2020). Changes in the heart's lymphatic structure are thought to increase the risks of heart disease by promoting oedema and inflammation, mainly due to poor lymphatic drainage (Bråkenhielm et al., 2020). Recently, we have discovered much more about the way cells work during ventricular remodelling in the past forties. Today, there is increased knowledge concerning the roles that sympathetic signals, inflammatory cytokines, and renin-angiotensin-aldosterone are able to play. Patients with heart failure get better outcomes if beta-blockers, ACE inhibitors, and mineralocorticoid receptor antagonists are used to treat the disease, at least partly due to decreased unfavourable ventricular remodelling.

A change in heart pressures can result in the heart altering its structure, which is known as cardiac plasticity. This skill matters a lot, especially when therapies that include side effects are developed (Pitoulis & Terracciano, 2020). The adaptation, nevertheless, often transforms into a harmful pattern

in people with ongoing heart failure. Evidently, within the heart, the connection between cardiomyocytes and various immune cells, fibroblasts, and endothelial cells is considered a major influence on cardiac remodelling, as reported by Bazgir et al. (2023). Myocardial fibrosis stems from inflammation in the heart tissue because of excessive calorie-rich food, obesity, and the effects of high blood pressure (Paulus & Zile, 2021).

A research on the relationship between vascular remodelling and allergic inflammation reveals that changes within the vessels could block airflow (Camargo et al., 2020). Fibrosis of the heart is mainly influenced by the way immune cells interact with cardiac fibroblasts (Feng et al., 2023). If the interaction is not properly regulated, there may be more collagen buildup and scarring, leading to worse remodelling of the ventricles (Goonoo, 2022). The utilization of new imaging techniques such as cardiac magnetic resonance imaging has significantly increased our knowledge of heart abnormalities caused by ventricular remodelling. A way to repair scarring in the heart could be through the use of pluripotent stem cells, hydrogels, and developments in nanotechnology (Schirone et al., 2022).

Molecular events such as metabolic changes, increased ROS levels, inflammation, trouble with autophagy, and issues with mitochondria begin when there is ischaemic injury to the heart muscle (Schirone et al., 2022). In people with chronic heart failure, another major factor in ventricular remodelling is metabolic remodelling, which means the heart shifts its energy source away from fatty acids to glucose. When heart metabolism changes for a long time, it can reduce energy production and cause the muscle to lose its strength in contracting. Systolic dysfunction and heart failure may result from abnormalities in how the heart uses fuel, intermediates, and cells respond to insulin, heat, and oxidative stress (Fan, Zhou, Zhang, et al., 2023). Xie et al. (2023) provide evidence that multiomics research has identified the detailed changes in metabolic state with aging. Managing metabolic problems may be an effective way to support heart function and prevent harmful changes in the heart muscle (Wang et al., 2021).

Now, it is clear that heart problems in the long and short term are caused, among other factors, by poor microvascular function in the heart (Fopiano et al., 2021). Mitochondria manage cellular quality by functioning in mitophagy and the release of pro-death components (Lotz et al., 2021). Researchers pay special attention to inventing new ways to support cardiac repair and regeneration, since the adult heart has little ability to renew itself. It refers to methods in tissue engineering, gene therapy, and using cells to treat damaged heart muscle and increase its functionality. They have been regarded as promising for cell-based therapy because they can adapt and grow into different cells (Chang et al., 2020).

## CONCLUSION

In this study, clinical, genetic, and imaging information was used to thoroughly assess ventricular remodelling in people with heart failure. We have observed that the worsening NYHA class is accompanied by gradually degrading biochemical and structural features. Those patients in higher NYHA categories showed a pattern of greater myocardial fibrosis, increased end-diastolic volume, high levels of NT-proBNP, TGF-β, and MMP9, and a significantly lower LVEF. Such changes in the heart are important because they prove the amount of damage, and demonstrate a risk of hospitalisation. It was determined that more cases of severe heart disease with over 25% fibrosis and LVEF less than

30% were seen in patients spending multiple nights in the hospital. According to studies, the higher the blood pressure, the more likely it is that the heart will have structural changes. Additionally, it seemed that male patients had slightly higher risk of being hospitalised and developing ventricular dilatation compared to females. Joannides et al. concluded that additional tests and imaging are needed to identify individuals with ALS more quickly, even as pharmacologic and device therapies are studied. By combining all of these features, the team discovered that understanding the remodelling continuum is easier and more accurate. Further research should focus on anti-fibrotic drugs, using various omics data, and tracking remodelling markers over time for each patient. To design medicines effective in heart failure, it is important to know how the heart is remodelled.

**REFERENCES**

Bazgir, F., Nau, J., Nakhaei-Rad, S., Amin, E., Wolf, M. J., Saucerman, J. J., Lorenz, K., & Ahmadian, M. R. (2023). The Microenvironment of the Pathogenesis of Cardiac Hypertrophy [Review of The Microenvironment of the Pathogenesis of Cardiac Hypertrophy]. Cells, 12(13), 1780. Multidisciplinary Digital Publishing Institute.

Bostan, M., Stătescu, C., Anghel, L., Șerban, I.-L., Cojocaru, E., & Sascău, R. A. (2020). Post-Myocardial Infarction Ventricular Remodeling Biomarkers—The Key Link between Pathophysiology and Clinic [Review of Post-Myocardial Infarction Ventricular Remodeling Biomarkers—The Key Link between Pathophysiology and Clinic]. Biomolecules, 10(11), 1587. Multidisciplinary Digital Publishing Institute.

Boulet, J., & Mehra, M. R. (2021). Left Ventricular Reverse Remodeling in Heart Failure: Remission to Recovery. Structural Heart, 5(5), 466.

Bråkenhielm, E., González, A., & Díez, J. (2020). Role of Cardiac Lymphatics in Myocardial Edema and Fibrosis [Review of Role of Cardiac Lymphatics in Myocardial Edema and Fibrosis]. Journal of the American College of Cardiology, 76(6), 735. Elsevier BV.

Calvieri, C., Riva, A., Sturla, F., Dominici, L., Conia, L., Gaudio, C., Miraldi, F., Secchi, F., & Galea, N. (2023). Left Ventricular Adverse Remodeling in Ischemic Heart Disease: Emerging Cardiac Magnetic Resonance Imaging Biomarkers [Review of Left Ventricular Adverse Remodeling in Ischemic Heart Disease: Emerging Cardiac Magnetic Resonance Imaging Biomarkers]. Journal of Clinical Medicine, 12(1), 334. Multidisciplinary Digital Publishing Institute.

Camargo, L. do N., Santos, T. M. dos, Andrade, F. C. P. de, Fukuzaki, S., Lopes, F. D. T. Q. dos S., Martins, M. A., Prado, C. M., Leick, E. A., Righetti, R. F., & Tibério, I. de F. L. C. (2020). Bronchial Vascular Remodeling Is Attenuated by Anti-IL-17 in Asthmatic Responses Exacerbated by LPS. Frontiers in Pharmacology, 11.

Chang, M., Chiu, Y., Li, J.-S., Cheah, K.-P., & Lin, H.-H. (2020). Analyzing Impetus of Regenerative Cellular Therapeutics in Myocardial Infarction [Review of Analyzing Impetus of Regenerative Cellular Therapeutics in Myocardial Infarction]. Journal of Clinical Medicine, 9(5), 1277. Multidisciplinary Digital Publishing Institute.

Chursina, T. Ya., Kravchenko, A. M., & Михалєв, К. О. (2022). LEFT VENTRICULAR REMODELING IN HEART FAILURE (PART I): CURRENT UNDERSTANDING OF PATHOMECHANISMS AND RELATED MYOCARDIAL DYSFUNCTION. Clinical and Preventive Medicine, 3, 71.

Fan, L., Meng, C., Wang, X., Wang, Y., Li, Y., Lv, S., & Zhang, J. (2023). Driving force of deteriorated cellular environment in heart failure: Metabolic remodeling [Review of Driving force of deteriorated cellular environment in heart failure: Metabolic remodeling]. Clinics, 78, 100263. Elsevier BV.

Feng, L., Chen, X., Huang, Y., Zhang, X., Zheng, S., & Xie, N. (2023). Immunometabolism changes in fibrosis: from mechanisms to therapeutic strategies [Review of Immunometabolism changes in fibrosis: from mechanisms to therapeutic strategies]. Frontiers in Pharmacology, 14. Frontiers Media.

Fopiano, K. A., Jalnapurkar, S., Davila, A., Arora, V., & Bagi, Z. (2021). Coronary Microvascular Dysfunction and Heart Failure with Preserved Ejection Fraction - implications for Chronic Inflammatory Mechanisms [Review of Coronary Microvascular Dysfunction and Heart Failure with Preserved Ejection Fraction - implications for Chronic Inflammatory Mechanisms]. Current Cardiology Reviews, 18(2). Bentham Science Publishers.

Frantz, S., Hundertmark, M., Schulz-Menger, J., Bengel, F. M., & Bauersachs, J. (2022). Left ventricular remodelling post-myocardial infarction: pathophysiology, imaging, and novel therapies [Review of Left ventricular remodelling post-myocardial infarction: pathophysiology, imaging, and novel therapies]. European Heart Journal, 43(27), 2549. Oxford University Press.

Gaetani, R., Zizzi, E. A., Deriu, M. A., Morbiducci, U., Pesce, M., & Messina, E. (2020). When Stiffness Matters: Mechanosensing in Heart Development and Disease [Review of When Stiffness Matters: Mechanosensing in Heart Development and Disease]. Frontiers in Cell and Developmental Biology, 8. Frontiers Media.

Garoffolo, G., Ferrari, S., Stefano, R. D., Barbuto, M., Bernava, G., & Pesce, M. (2020). Harnessing Mechanosensation in Next Generation Cardiovascular Tissue Engineering [Review of Harnessing Mechanosensation in Next Generation Cardiovascular Tissue Engineering]. Biomolecules, 10(10), 1419. Multidisciplinary Digital Publishing Institute.

Goonoo, N. (2022). Tunable biomaterials for myocardial tissue regeneration: promising new strategies for advanced biointerface control and improved therapeutic outcomes [Review of Tunable biomaterials for myocardial tissue regeneration: promising new strategies for advanced biointerface control and improved therapeutic outcomes]. Biomaterials Science, 10(7), 1626. Royal Society of Chemistry.

Hnát, T., Veselka, J., & Honěk, J. (2022). Left ventricular reverse remodelling and its predictors in non-ischaemic cardiomyopathy [Review of Left ventricular reverse remodelling and its predictors in non-ischaemic cardiomyopathy]. ESC Heart Failure, 9(4), 2070. Wiley.

Janssens, K. L. P. M., Kraamer, M., Barbarotta, L., & Bovendeerd, P. H. M. (2023). Post-infarct evolution of ventricular and myocardial function. Biomechanics and Modeling in Mechanobiology, 22(6), 1815.

Jenča, D., Melenovský, V., Stehlik, J., Staněk, V., Kettner, J., Kautzner, J., Adámkova, V., & Wohlfahrt, P. (2020). Heart failure after myocardial infarction: incidence and predictors [Review of Heart failure after myocardial infarction: incidence and predictors]. ESC Heart Failure, 8(1), 222. Wiley.

Leancă, S. A., Crișu, D., Petriș, A. O., Afrăsânie, I., Genes, A., Costache, A. D., Tesloianu, D., & Costache, I. I. (2022). Left Ventricular Remodeling

after Myocardial Infarction: From Physiopathology to Treatment [Review of Left Ventricular Remodeling after Myocardial Infarction: From Physiopathology to Treatment]. Life, 12(8), 1111. Multidisciplinary Digital Publishing Institute.

Lotz, C., Herrmann, J., Notz, Q., Meybohm, P., & Kehl, F. (2021). Mitochondria and Pharmacologic Cardiac Conditioning—At the Heart of Ischemic Injury [Review of Mitochondria and Pharmacologic Cardiac Conditioning—At the Heart of Ischemic Injury]. International Journal of Molecular Sciences, 22(6), 3224. Multidisciplinary Digital Publishing Institute.

Nso, N., Bookani, K. R., Metzl, M. D., & Radparvar, F. (2020). Role of inflammation in atrial fibrillation: A comprehensive review of current knowledge [Review of Role of inflammation in atrial fibrillation: A comprehensive review of current knowledge]. Journal of Arrhythmia, 37(1), 1. Elsevier BV.

Paulus, W. J., & Zile, M. R. (2021). From Systemic Inflammation to Myocardial Fibrosis [Review of From Systemic Inflammation to Myocardial Fibrosis]. Circulation Research, 128(10), 1451. Lippincott Williams & Wilkins.

Pitoulis, F. G., & Terracciano, C. M. (2020). Heart Plasticity in Response to Pressure- and Volume-Overload: A Review of Findings in Compensated and Decompensated Phenotypes [Review of Heart Plasticity in Response to Pressure- and Volume-Overload: A Review of Findings in Compensated and Decompensated Phenotypes]. Frontiers in Physiology, 11. Frontiers Media.

Razavi, Z., Soltani, M., Mahmoudvand, G., Farokhi, S., Karimi-Rouzbahani, A., Farasati-Far, B., Tahmasebi-Ghorabi, S., Pazoki–Toroudi, H., & Afkhami, H. (2024). Advancements in tissue engineering for cardiovascular health: a biomedical engineering perspective. Frontiers in Bioengineering and Biotechnology, 12.

Raziyeva, K., Kim, Y., Zharkinbekov, Z., Temirkhanova, K., & Saparov, A. (2022). Novel Therapies for the Treatment of Cardiac Fibrosis Following Myocardial Infarction [Review of Novel Therapies for the Treatment of Cardiac Fibrosis Following Myocardial Infarction]. Biomedicines, 10(9), 2178. Multidisciplinary Digital Publishing Institute.

Scalise, R. F. M., Sarro, R. D., Caracciolo, A., Lauro, R., Squadrito, F., Carerj, S., Bitto, A., Micari, A., Bella, G. D., Costa, F., & Irrera, N. (2021). Fibrosis after Myocardial Infarction: An Overview on Cellular Processes, Molecular Pathways, Clinical Evaluation and Prognostic Value [Review of Fibrosis after Myocardial Infarction: An Overview on Cellular Processes, Molecular Pathways, Clinical Evaluation and Prognostic Value]. Medical Sciences, 9(1), 16. Multidisciplinary Digital Publishing Institute.

Schirone, L., Forte, M., D'Ambrosio, L., Valenti, V., Vecchio, D., Schiavon, S., Spinosa, G., Sarto, G., Petrozza, V., Frati, G., & Sciarretta, S. (2022). An Overview of the Molecular Mechanisms Associated with Myocardial Ischemic Injury: State of the Art and Translational Perspectives [Review of An Overview of the Molecular Mechanisms Associated with Myocardial Ischemic Injury: State of the Art and Translational Perspectives]. Cells, 11(7), 1165. Multidisciplinary Digital Publishing Institute.

Schwinger, R. H. G. (2021). Pathophysiology of heart failure [Review of Pathophysiology of heart failure]. Cardiovascular Diagnosis and Therapy, 11(1), 263. AME Publishing Company.

Singh, K., Gupta, A., Sarkar, A., Gupta, I., Rana, S., Sarkar, S., & Khan, S. (2020). Arginyltransferase

knockdown attenuates cardiac hypertrophy and fibrosis through TAK1-JNK1/2 pathway. Scientific Reports, 10(1).

Tóth, P. P., & Gauthier, D. F. (2020). Heart failure with preserved ejection fraction: strategies for disease management and emerging therapeutic approaches [Review of Heart failure with preserved ejection fraction: strategies for disease management and emerging therapeutic approaches]. Postgraduate Medicine, 133(2), 125. Taylor & Francis.

Wang, S., Zhang, J., Wang, Y., Jiang, X., Guo, M., & Yang, Z. (2021). NLRP3 inflammasome as a novel therapeutic target for heart failure. The Anatolian Journal of Cardiology, 26(1), 15.

Webber, M., Jackson, S. P., Moon, J., & Captur, G. (2020). Myocardial Fibrosis in Heart Failure: Anti-Fibrotic Therapies and the Role of Cardiovascular Magnetic Resonance in Drug Trials [Review of Myocardial Fibrosis in Heart Failure: Anti-Fibrotic Therapies and the Role of Cardiovascular Magnetic Resonance in Drug Trials]. Cardiology and Therapy, 9(2), 363. Adis, Springer Healthcare.

Xie, S., Xu, S., Deng, W., & Tang, Q. (2023). Metabolic landscape in cardiac aging: insights into molecular biology and therapeutic implications [Review of Metabolic landscape in cardiac aging: insights into molecular biology and therapeutic implications]. Signal Transduction and Targeted Therapy, 8(1). Springer Nature.

Zhao, C., Yan, L., Liu, Y., Chen, S., Lan, D., Liu, R., Xin, J., Tao, S., & Yang, X. (2025). Effect of CBC-Derived Inflammatory Indicators in Predicting Chronic Kidney Disease Risk in Hypertrophic Cardiomyopathy Patients. Biomedicines, 13(4), 997.

Zhao, W., Zhao, J., & Rong, J. (2020). Pharmacological Modulation of Cardiac Remodeling after Myocardial Infarction [Review of Pharmacological Modulation of Cardiac Remodeling after Myocardial Infarction]. Oxidative Medicine and Cellular Longevity, 2020, 1. Hindawi Publishing Corporation.